仑伐替尼治疗筛状-桑葚状变异型甲状腺乳头状癌伴肺转移及APC突变一例
本文报道一例24岁女性筛状-桑葚状变异型甲状腺乳头状癌(CMV-PTC)伴家族性腺瘤性息肉病(FAP)及APC胚系突变患者,术后三年半出现多发肺转移,起始仑伐替尼24 mg治疗一个月后肺转移显著缩小,持续治疗24个月(现剂量10 mg)肺转移未进展;仑伐替尼治疗后内镜下仅见少数小息肉新生,而治疗前每次内镜平均切除21-75枚息肉。
要点
- CMV-PTC伴APC突变患者术后需警惕远处转移,本例术后三年半出现肺转移。
- 仑伐替尼24 mg起始治疗一个月后肺转移显著缩小,持续24个月未进展。
- 仑伐替尼治疗后FAP息肉新生数量较治疗前明显减少。
核心结论
- 仑伐替尼对CMV-PTC远处转移有效,并对伴发的FAP息肉管理显示潜力。
研究设计与样本
- 个案报道:一例24岁女性CMV-PTC伴FAP及APC胚系突变患者。
主要发现
- 术后三年半检出多发大肺转移,起始仑伐替尼24 mg治疗一个月后肺转移显著缩小。
- 持续仑伐替尼治疗24个月(现剂量10 mg),肺转移未进展。
- 仑伐替尼治疗后内镜仅见少数小息肉新生,治疗前每次内镜平均切除21-75枚息肉。
关键数值与推荐
- 仑伐替尼起始剂量24 mg,治疗一个月后肺转移显著缩小。
- 持续治疗24个月,现剂量10 mg,肺转移未进展。
- 治疗前每次内镜平均切除21-75枚息肉,治疗后仅少数小息肉新生。
临床怎么用
- CMV-PTC伴APC突变患者术后应监测远处转移。
- 仑伐替尼可用于CMV-PTC远处转移治疗,并可能有利于FAP息肉管理。
- 该策略或适用于复发CMV-PTC及拒绝结肠切除术的FAP患者。
局限性
- 仅为单例个案报道,结论需更多研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The cribriform-morular variant (CMV) is a rare subtype of papillary thyroid carcinoma (PTC), and is often associated with familial adenomatous polyposis (FAP). This variant is generally indolent, but some aggressive cases have been reported. Patient Findings: We present the case of a 24-year-old woman who underwent total thyroidectomy with prophylactic central lymph node dissection and modified radical neck dissection for CMV-PTC. No distant metastases were identified preoperatively. However, multiple large lung metastases were detected three and half years after surgery. She also had FAP with a germline APC gene mutation. Summary: She was started on lenvatinib because of the metastatic disease. One month after the initiation of lenvatinib (24 mg), her lung metastases reduced significantly. She has continued lenvatinib for 24 months (present dose, 10 mg). The lung metastases have not progressed during this period. Only a few small polyps were newly detected on endoscopy after lenvatinib administration. This number was considerably higher before therapy, when an average of 21-75 polyps were resected at each endoscopy session. Conclusions: This is the first report of the use of lenvatinib for the treatment of distant metastases from CMV-PTC. In addition to the efficacy in treating metastatic lesions of this rare variant of PTC, lenvatinib shows promise in the management of associated FAP. This treatment strategy may be useful in the management of recurrent CMV-PTC and in those with FAP who refuse colectomy.
引用
- Ito Y, Ishikawa H, Kihara M, et al. Control of Lung Metastases and Colon Polyposis with Lenvatinib Therapy in a Patient with Cribriform-Morular Variant of Papillary Thyroid Carcinoma and an APC Gene Mutation: A Case Study. Thyroid. 2019. PMID: 31317827. doi:10.1089/thy.2019.0121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。